ArticleCardiovascular journal of Africa
A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa.
Article in Cardiovascular journal of Africa. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- Systematic review and meta-analysis of AI accuracy in warfarin dose prediction across ethnic groups.European journal of clinical pharmacology · 2026Pooled it
- Warfarin-Associated Bleeding and Thromboembolic Events in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.Pharmacoepidemiology and drug safety · 2025Pooled it
- Anticoagulation quality through time in therapeutic range in Sub-Saharan Africa: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Severity and Hospitalization Cost Related to Warfarin-Related Adverse Events in a Tertiary Malaysian Hospital.Hospital pharmacy · 2022Article
- Improving anticoagulation in sub-Saharan Africa: What are the challenges and how can we overcome them?British journal of clinical pharmacology · 2021Review
- Dying to be Ill: Munchausen meets warfarin overdose.Journal of family medicine and primary care · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWarfarin is a widely used anticoagulant for the prevention and treatment of thromboembolism. We conducted a retrospective review to determine the causes and management of warfarin toxicity of patients admitted to Tygerberg hospital between June 2014 and June 2015.
resultsWe identified and evaluated 126 patients who met the inclusion criteria. The cause of warfarin toxicity was identified and addressed in only 14.3% (18/126) of patients. Where the cause was identified, 56% (10/18) was due to dosing errors and 17% (3/18) drug-drug interaction (DDI). However, 77% (97/126) of patients were retrospectively identified as receiving concomitant medicines known to interact with warfarin at the time of admission. Twenty-eight percent (35/126) of patients presented with major bleeding, which included seven cases of intracranial haemorrhage. Patients were admitted for a median of eight days at an average treatment cost of R10 578.
conclusionWe found that warfarin toxicity carries significant mortality and cost, but little attention is paid to the causes of toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.